Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by BAP1 localizes to the nucleus and it interacts with the RING finger domain of the breast cancer 1, early onset protein (BRCA1). Additionally we are shipping BAP1 Proteins (7) and BAP1 Kits (3) and many more products for this protein.
Showing 10 out of 115 products:
Human Monoclonal BAP1 Primary Antibody for IF, WB - ABIN1105494
Jensen, Proctor, Marquis, Gardner, Ha, Chodosh, Ishov, Tommerup, Vissing, Sekido, Minna, Borodovsky, Schultz, Wilkinson, Maul, Barlev, Berger, Prendergast, Rauscher: BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. in Oncogene 1998
Human Polyclonal BAP1 Primary Antibody for IHC (p), WB - ABIN388948
Abdel-Rahman, Pilarski, Cebulla, Massengill, Christopher, Boru, Hovland, Davidorf: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. in Journal of medical genetics 2011
BAP1(+/-) mice exposed to low-dose asbestos fibers showed an altered peritoneal inflammatory response and higher levels of pro-tumorigenic alternatively polarized M2 macrophages, and lower cytokine levels. They had a higher incidence of mesothelioma.
Bap1 loss led to a fully penetrant myeloproliferative disease with splenomegaly, leukocytosis, anemia and progenitor expansion via alterations in histone methylation and gene expression.
INO80 (show INO80 Antibodies) is stabilized and targeted to replication forks by BAP1 during normal DNA synthesis but downregulated in BAP1 defective cancer cells
Both Vhl (show VHL Antibodies) and Bap1 are required for kidney function. Inactivation of Bap1 in neprhon progenitor cells causes renal failure earlier than Vhl (show VHL Antibodies) inactivation. Bap1 is also a stronger tumor suppressor gene than Vhl (show VHL Antibodies) in the kidney.
Drawing parallels to human disease, these unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.
Cx32 (show GJB1 Antibodies) expression is in part related to induction of tight junctions through modulation of Magi1 (show CNKSR3 Antibodies) expression in an immortalized hepatic cell line.
ARIP1 (show MAGI2 Antibodies) and ARIP2 (show SYNJ2BP Antibodies) are co-expressed in some nerve cells and their biological activities are distinct.
results identify a potent tumor suppressor function for BAP1 in myeloid neoplasia; propose that BAP1 forms a core complex with HCF-1 (show HCFC1 Antibodies) and OGT (show OGT Antibodies) that can differentially recruit additional histone-modifying enzymes to regulate gene expression and preserve norm
Data conclude that the up-regulation of sdk-1 (show SDK1 Antibodies) in podocytes is an important pathogenic factor in glomerulosclerosis and that the mechanism involves disruption of the actin cytoskeleton possibly via alterations in MAGI-1 (show CNKSR3 Antibodies) function.
Depletion of MAGI-1 (show CNKSR3 Antibodies) from photorecptors by RNA interference blocks synaptic localization of Sidekick-2 (show SDK2 Antibodies) in photoreceptors without affecting localization of postsynaptic density (PSD)-95 (show DLG4 Antibodies).
Unusually high frequency of large deletions indicates that the 3p21 chromosomal region surrounding BAP1 (show RNF2 Antibodies) gene is structurally unstable.
BAP1 (show RNF2 Antibodies) immunohistochemistry is relatively insensitive in the context of differential diagnosis of sarcomatous and desmoplastic mesotheliomas.
loss of BAP1 (show RNF2 Antibodies) expression can be used to very strongly support a pathological diagnosis of abdominal mesothelioma over serous carcinoma
conclude that loss of BAP1 (show RNF2 Antibodies) expression, while not definitive, can be used to support the diagnosis of mesothelioma in effusion cytology
Use bioinformatic tools to predict the molecular effects of all mutations lying in BAP1 (show RNF2 Antibodies) genes.
We conclude that, in contrast to intrahepatic cholangiocarcinoma, loss of expression of BAP1 (show RNF2 Antibodies) occurs very rarely in pancreatic ductal adenocarcinoma. Therefore BAP1 (show RNF2 Antibodies) inactivation is unlikely to be a frequent driver abnormality in pancreatic adenocarcinoma
identifies a new BAP1 (show RNF2 Antibodies) mutation, further highlights the relevance of BAP1 (show RNF2 Antibodies) as a clinically important tumor suppressor gene, and broadens the range of cancers associated with BAP1 (show RNF2 Antibodies) inactivation
Many tumors harboring BAP1 (show RNF2 Antibodies) germline mutations were associated with BAP1 (show RNF2 Antibodies) syndrome, including mesothelioma and ocular/cutaneous melanomas, as well as renal, breast, lung, gastric, and basal cell carcinomas.
Cellular blue nevi showed normal positive IHC staining for BAP1 (show RNF2 Antibodies). Loss of BAP1 (show RNF2 Antibodies) IHC expression was restricted to melanomas. including all metastatic cases
BAP1 (show RNF2 Antibodies) interacts directly with KLF5 (show KLF5 Antibodies) and stabilizes KLF5 (show KLF5 Antibodies) via deubiquitination.
The protein encoded by this gene localizes to the nucleus and it interacts with the RING finger domain of the breast cancer 1, early onset protein (BRCA1). This gene is thought to be a tumor suppressor gene that functions in the BRCA1 growth control pathway. There are multiple polyadenylation sites found in this gene.
BRCA1-associated protein 1
, ubiquitin C-terminal hydrolase X4
, ubiquitin carboxyl-terminal hydrolase BAP1
, cerebral protein 6
, cerebral protein-13
, Brca1 associated protein 1
, BAI1-associated protein 3
, ubiquitin carboxy-terminal hydrolase
, BAI1-associated protein 1
, guanylate kinase membrane-associated inverted 1
, membrane-associated guanylate kinase inverted 1
, membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1